A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
DEKA Biosciences
Eli Lilly and Company
OHSU Knight Cancer Institute
Emory University
Gilead Sciences
Celgene
City of Hope Medical Center